Y-Intercept (HK)’s Verrica Pharmaceuticals VRCA Stock Holding History

Y-Intercept (HK)’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,696	Closed	-$99.1K	–	2092
2025 Q2	$99.1K	Buy	+18,696	New	+$101K	﹤0.01%	1535

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Y-Intercept (HK)'s VRCA Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 18,696 shares — an estimated $99.1K sold.

Y-Intercept (HK) first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $99.1K in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

Y-Intercept (HK) reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 18,696 Verrica Pharmaceuticals shares in Q3 2025, an estimated $99.1K.
Y-Intercept (HK) first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Verrica Pharmaceuticals position peaked at $99.1K in Q2 2025.
34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.